Early indications of future cognitive decline: stable versus declining controls

Area of Science:

• Neuroimaging and Cognitive Science
• Biomarkers of Neurodegeneration

Background:

• Identifying individuals at risk for cognitive decline is crucial for early intervention.
• Subtle baseline differences in healthy individuals may predict future cognitive impairment.

Purpose of the Study:

• To identify baseline clinical and neuroimaging features distinguishing cognitively healthy individuals with future cognitive decline from those who remain stable.
• To assess the predictive capability of these features for cognitive decline within 48 months.

Main Methods:

• Utilized publicly available data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
• Employed linear regression and Linear Discriminant Analysis (LDA) models.
• Analyzed baseline clinical assessments (ADAScog, AVLT, FAQ) and neuroimaging measures (MRI, FDG-PET).

Main Results:

• Specific baseline neuroimaging measures, including posterior cingulate glucose metabolism, were significantly associated with subsequent cognitive decline.
• LDA models incorporating MRI and FDG-PET data accurately predicted conversion to Mild Cognitive Impairment (MCI) or cognitive stability within 48 months.

Conclusions:

• Informative differences exist between healthy individuals who will develop cognitive impairment and those who will remain stable.
• Predictive models using baseline neuroimaging and clinical data show feasibility for detecting early cognitive decline in asymptomatic individuals.